Sylvia Dobo

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Bruce L. Zuraw, William R. Lumry, Douglas Johnston et al. · Journal of Allergy and Clinical Immunology · 2020 · 155 citations · Full text

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Emel Aygören‐Pürsün, Anette Bygum, Vesna Grivcheva‐Panovska et al. · New England Journal of Medicine · 2018 · 111 citations · Full text

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Henriette Farkas, Marcin Stobiecki, Jonny Peter et al. · Clinical and Translational Allergy · 2021 · 50 citations · Full text

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

Isao Ohsawa, Daisuke Honda, Yusuke Suzuki et al. · Allergy · 2020 · 45 citations · Full text

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp>‐2 study

Marc A. Riedl, Emel Aygören‐Pürsün, James Baker et al. · Allergy · 2018 · 39 citations · Full text